Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd (SUDARSHAN) last traded at ₹39, a market capitalisation of ₹973 crore, on a P/E of 38.7. Over the past 52 weeks the stock has ranged between ₹18.5 and ₹42.8. Sudarshan Pharma Industries Ltd last reported results for the quarter ended Jun 2026, with sales of ₹174 crore and net profit of ₹5.61 crore. The next scheduled event is a merger acquisition on 10 Oct 2026. Figures are as of 25 Aug 2026 and are not real time.
Sudarshan Pharma Industries Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Sudarshan Pharma Industries Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹174 cr, up 20.1% from ₹145 cr a year earlier. Net profit was ₹5.61 cr, up 41.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 116 | 162 | 145 | 169 | 168 | 221 | 174 |
| Expenses | 116 | 108 | 146 | 134 | 160 | 157 | 201 | 159 |
| Operating profit | 13.05 | 7.97 | 15.93 | 11.04 | 9.21 | 10.87 | 20.2 | 15.9 |
| OPM % | 10.15% | 6.89% | 9.86% | 7.60% | 5.45% | 6.47% | 9.14% | 9.12% |
| Other income | -0.85 | 0.51 | -0.81 | 1.21 | 1.86 | 1.52 | 4.13 | 1.22 |
| Interest | 3.7 | 4 | 4.4 | 5.96 | 5.94 | 6.28 | 7.53 | 8.21 |
| Depreciation | 0.67 | 0.63 | 0.83 | 0.88 | 0.9 | 0.91 | 1.09 | 1.41 |
| Profit before tax | 7.83 | 3.85 | 9.89 | 5.41 | 4.23 | 5.2 | 15.71 | 7.5 |
| Tax % | 24.90% | 24.94% | 25.08% | 26.80% | 8.51% | 20.19% | 27.43% | 25.33% |
| Net profit | 5.88 | 2.88 | 7.41 | 3.96 | 3.87 | 4.15 | 11.4 | 5.61 |
| EPS (₹) | 0.24 | 0.12 | 0.31 | 0.17 | 0.17 | 0.18 | 0.45 | 0.23 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sudarshan Pharma Industries Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 193 | 357 | 461 | 464 | 505 | 703 | 732 |
| Operating profit | 7 | 11 | 15 | 23 | 40 | 51 | 56 |
| OPM % | 3.7% | 3.1% | 3.2% | 4.9% | 8% | 7% | 8% |
| Net profit | 3 | 5 | 7 | 11 | 16 | 23 | 25 |
| EPS (₹) | 0.28 | 0.54 | 0.29 | 0.48 | 0.66 | 0.97 | 1.03 |
TTM is the trailing twelve months to the most recent quarter.
Sudarshan Pharma Industries Ltd growth and returns
- 10 Years
- %
- 5 Years
- 29%
- 3 Years
- 15%
- TTM
- 33%
- 10 Years
- %
- 5 Years
- 54%
- 3 Years
- 48%
- TTM
- 13%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 70%
- 1 Year
- 17%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 14%
- Last Year
- 16%
Sudarshan Pharma Industries Ltd shareholding pattern
Promoters held 58.93% at Aug 2026, up from 57.39% at Sep 2025. FIIs 19.88%.
| % held | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% | 57.39% | 58.93% | 58.93% |
| FIIs | 13.07% | 18.45% | 19.49% | 20.79% | 19.78% | 19.95% | 19.38% | 19.88% |
| Government | 0.00% | 0.00% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Public | 29.54% | 24.16% | 23.07% | 21.76% | 22.79% | 22.61% | 21.65% | 21.15% |
| No. of shareholders | 787 | 1,212 | 1,327 | 1,383 | 1,407 | 1,346 | 1,231 | 1,217 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Sudarshan Pharma Industries Ltd events
The next scheduled event is a merger acquisition on 10 Oct 2026.
- Merger acquisitionAcquisition of 76% stake in a pharmaceutical manufacturing plant for backward integration
- Merger acquisitionAcquisition of remaining 30% stake in subsidiary Sudarshan Maven Pharma Private Limited
See the full results calendar for every Indian company reporting in the next 30 days.
Sudarshan Pharma Industries Ltd corporate filings
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 21, 2026 for Hemal V Mehta & Sachin V MehtaInsider Trading / SASTmedium impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has disclosed that its promoters, Hemal V Mehta and…
Read the full analysis - It is hereby informed that the members of the FCCB COmmittee of the COmpany, have at their meeting held today, 19/Aug/2026, have approved allotment of 48,11,730 fully paid-up equity shares ....Company Updatemedium impact
Cruxal's analysis: Sudarshan Pharma Industries has approved the allotment of 48,11,730 fully paid-up equity…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has released its unaudited financial results for the…
Read the full analysis - Pursuant to Regulation 30 of SEBI LODR Regulations, We hereby submit the updated Investor PresentationCompany Updatehigh impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has released an updated investor presentation…
Read the full analysis - The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Vasantrai Ratilal ....Insider Trading / SASTmedium impact
Cruxal's analysis: Sudarshan Pharma Industries has disclosed the creation of a pledge on 65.81 lakh equity…
Read the full analysis - A Meeting of the FCCB Committee of the Company is scheduled on Wednesday, 19-August-2026 to consider and approve conversion a portion of funds raised through FCCBs into equity shares and ....Company Updatemedium impact
Cruxal's analysis: Sudarshan Pharma Industries has scheduled a meeting of its FCCB Committee for August 19…
Read the full analysis - We hereby submit the presentation on the manufacturing plant proposed to be acquired by the Company.Company Updatehigh impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has disclosed a presentation regarding the proposed…
Read the full analysis - The Company has entered into a Memorandum of Understanding to acquire 1,24,64,000 equity shares of Rs.10/- each of the target company (76% of paid up equity share capital). The acquisition ....Company Updatehigh impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has entered into a Memorandum of Understanding to…
Read the full analysis - The Board of Directors at their Meeting held on 12/August/2026 approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited. ....Company Updatemedium impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has received board approval to divest 2,09,100 equity…
Read the full analysis - The Board of Directors at their meeting held on 12/August/2026 approved to acquire 3,000 equity shares (30.00% of paid up capital) of Sudarshan Maven Pharma Private Limited. Upon acqusition, ....Company Updatelow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has announced the acquisition of 3,000 equity shares of…
Read the full analysis - Financial Results For The Quarter Ended 30/06/2026Resulthigh impact
Cruxal's analysis: Sudarshan Pharma Industries Limited reported Q1 FY27 consolidated revenue of 174.42…
Read the full analysis - The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 08, 2026 for Hemal Vasantrai MehtaInsider Trading / SASTmedium impact
Cruxal's analysis: Sudarshan Pharma Industries Limited has disclosed the release of 20 lakh shares from a…
Read the full analysis - Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Unaudited Standalone ....Board Meetinglow impact
Cruxal's analysis: Sudarshan Pharma Industries Ltd has formally notified the BSE of a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Sudarshan Pharma Industries Ltd
Cruxal reads every Sudarshan Pharma Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.